Lupus (SLE) trials in China
163 trials · From ClinicalTrials.gov, checked 10 Nov 2026. Ask the study team whether a trial fits you.
Phase 1RecruitingTrial-stage medicine
CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
- Where
- Beijing
- Age
- 18 years to 60 years
- People
- 27
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT06822881Registry updated 2026-03-10
Phase 1/2RecruitingTrial-stage medicine
A Study of GR1803 in Systemic Lupus Erythematosus
- Where
- Wuhan
- Age
- 18 years to 60 years
- People
- 44
- Run by
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
See details and how to joinNCT07348055Registry updated 2026-03-10
Phase 1RecruitingTrial-stage medicine
An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
- Where
- Bengbu
- Age
- 18 years to 65 years
- People
- 18
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07236762Registry updated 2026-03-04
Phase 1/2RecruitingTrial-stage medicine
Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
- Where
- Beijing
- Age
- 6 years to 65 years
- People
- 45
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT06947473Registry updated 2026-03-03
Phase 1RecruitingTrial-stage medicine
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
- Where
- Xuzhou
- Age
- 18 years to 65 years
- People
- 18
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07236801Registry updated 2026-03-02
Phase 1RecruitingTrial-stage medicine
A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
- Where
- Beijing, Hefei, Wuhan
- Age
- 18 years to 65 years
- People
- 18
- Run by
- Hangzhou Qihan Biotech Co., Ltd.
See details and how to joinNCT07444307Registry updated 2026-03-02
Phase 1Not yet recruitingTrial-stage medicine
YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases
- Where
- Shanghai
- Age
- 5 years to 18 years
- People
- 12
- Run by
- Children's Hospital of Fudan University
See details and how to joinNCT07439029Registry updated 2026-02-27
Early phase 1RecruitingTrial-stage medicine
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
- Where
- Shanghai
- Age
- 18 years to 70 years
- People
- 60
- Run by
- Changhai Hospital
See details and how to joinNCT07246096Registry updated 2026-02-25
Phase 1RecruitingTrial-stage medicine
Study of CD19 CAR-T Therapy for Refractory SLE
- Where
- Chongqing
- Age
- 5 years and over
- People
- 18
- Run by
- Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT07403097Registry updated 2026-02-11
Phase 2Not yet recruitingTrial-stage medicine
A Multicenter Phase 2a Clinical Study to Evaluate SIM0278 in Subjects With Active Lupus Nephritis
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 60
- Run by
- Simcere Pharmaceutical Co., Ltd
See details and how to joinNCT07393451Registry updated 2026-02-06
Phase 1/2RecruitingTrial-stage medicine
Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 189
- Run by
- Excyte Biopharma Ltd
See details and how to joinNCT07010835Registry updated 2026-02-05
Phase 1RecruitingTrial-stage medicine
Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE
- Where
- Nanjing
- Age
- 18 years and over
- People
- 18
- Run by
- Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT07318259Registry updated 2026-02-03
No phaseNot yet recruitingResearch participation
A Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus.
- Where
- Jinan
- Age
- 18 years to 65 years
- People
- 180
- Run by
- Yipeng Liu
See details and how to joinNCT07069972Registry updated 2026-02-02
Phase 1RecruitingTrial-stage medicine
A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
- Where
- Bengbu, Changsha, Guangzhou, Nanchang, Xuzhou
- Age
- 18 years to 70 years
- People
- 38
- Run by
- Nanjing Legend Biotech Co.
See details and how to joinNCT07331272Registry updated 2026-02-02
Phase 1Not yet recruitingTrial-stage medicine
The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE
- Where
- Beijing
- Age
- 18 years and over
- People
- 32
- Run by
- HC Biopharma Inc.
See details and how to joinNCT07306585Registry updated 2026-01-28
Phase 4RecruitingTrial-stage medicine
Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
- Where
- Wuhan
- Age
- 18 years to 80 years
- People
- 100
- Run by
- Tongji Hospital
See details and how to joinNCT07077486Registry updated 2026-01-27
Phase 1RecruitingTrial-stage medicine
UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
- Where
- Nanjing
- Age
- 18 years to 65 years
- People
- 21
- Run by
- Nanjing IASO Biotechnology Co., Ltd.
See details and how to joinNCT07109986Registry updated 2026-01-23
Phase 2RecruitingTrial-stage medicine
Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN
- Where
- Nanjing
- Age
- 18 years to 75 years
- People
- 105
- Run by
- Haisco Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07363460Registry updated 2026-01-23
Phase 1Not yet recruitingTrial-stage medicine
KN5501 Cell Injection for Refractory SLE(CLEAR)
- Where
- Beijing, Bengbu, Luoyang, Nanjing, Shanghai, Wuhan
- Age
- 18 years to 70 years
- People
- 36
- Run by
- Ruitherapeutics Co., LTD
See details and how to joinNCT07358988Registry updated 2026-01-22
Phase 1RecruitingTrial-stage medicine
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
- Where
- Tianjin
- Age
- 18 years and over
- People
- 12
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07315087Registry updated 2026-01-20
No phaseRecruitingResearch participation
Immune Profiling of Refractory cSLE Exposed to CD3×CD19 BiTE
- Where
- Hangzhou
- Age
- 5 years and over
- People
- 6
- Run by
- The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07352332Registry updated 2026-01-20
Early phase 1RecruitingResearch participation
A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus
- Where
- Wuhan
- Age
- 18 years to 65 years
- People
- 12
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07339332Registry updated 2026-01-14
Phase 1RecruitingTrial-stage medicine
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
- Where
- Nanjing
- Age
- 18 years and over
- People
- 18
- Run by
- Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT07331467Registry updated 2026-01-12
No phaseNot yet recruitingTrial-stage medicine
ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
- Where
- Wuhan
- Age
- 18 years to 60 years
- People
- 22
- Run by
- Tongji Hospital
See details and how to joinNCT07314567Registry updated 2026-01-02
No phaseRecruitingTrial-stage medicine
Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
- Where
- Hangzhou
- Age
- 18 years to 65 years
- People
- 15
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06614270Registry updated 2025-12-29
All Lupus (SLE) trials and the map
This page is not medical advice. Talk to your doctor before contacting a trial.